RxDoctor Payments Data

Li Li, MD

General Practice · Sacramento, CANPI 1710959523

Payments from drug & device makers

$12,577in general payments, 2019–2025

Across 636 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • AbbVie$2K
  • GSK$2K
  • Bayer$731
  • Amarin Pharma, Inc.$689
  • Sanofi-aventis U.S. LLC$431
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$1,0709%
  • Food & beverage$11,40391%
  • Education$1041%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,577 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$72,758
Medicare patients
196
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$98,112
VraylarCariprazine Hcl39$60,590
FarxigaDapagliflozin Propanediol50$54,975
JardianceEmpagliflozin39$47,413
JanuviaSitagliptin Phosphate35$45,568
TradjentaLinagliptin33$35,356
EliquisApixaban26$34,165
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$33,640
VascepaIcosapent Ethyl72$33,065
LinzessLinaclotide34$31,909
Breo ElliptaFluticasone/Vilanterol62$31,574
RybelsusSemaglutide17$29,676
Janumet XrSitagliptin Phos/Metformin Hcl20$24,760
TrulicityDulaglutide16$22,648
KerendiaFinerenone21$21,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$312$127,788119 claims
AbbVieVraylar, Linzess$1,907$92,49973 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$246$92,10384 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,750$80,142112 claims
MerckJanuvia, Janumet Xr$395$70,32955 claims
AstraZenecaFarxiga, Breztri Aerosphere$389$64,05462 claims
PfizerEliquis$358$34,16526 claims
Lilly USA, LLCTrulicity$396$22,64816 claims
BayerKerendia$731$21,91221 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$297$19,59612 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$431$12,46812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →